1-15 of 15
Jonas A. Nilsson
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract 6436: Tumor-educated platelets for therapy stratification of metastasized castration resistant prostate cancer (CRPC)

Jonas A. Nilsson, Marie Lundholm, Lee-Ann Tjon-Kon-Fat, Linda Köhn, Camilla Thellenberg-Karlsson, Andreas Josefsson, Pernilla Wikström
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 6436.
https://doi.org/10.1158/1538-7445.AM2024-6436
Published: 22 March 2024
View articletitled, Abstract 6436: Tumor-educated platelets for therapy stratification of metastasized castration resistant prostate cancer (CRPC)
Journal Articles

Abstract 530: UMAP- Personalized lung cancer monitoring platform

Zahra Haider, Linda Köhn, Nicholas Karlowatz, Mikael B. Johansson, Jonas A. Nilsson
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 530.
https://doi.org/10.1158/1538-7445.AM2022-530
Published: 15 June 2022
View articletitled, Abstract 530: UMAP- Personalized lung cancer monitoring platform
Journal Articles

HER2 CAR-T Cells Eradicate Uveal Melanoma and T-cell Therapy–Resistant Human Melanoma in IL2 Transgenic NOD/SCID IL2 Receptor Knockout Mice

Elin M.V. Forsberg, Mattias F. Lindberg, Henrik Jespersen, Samuel Alsén, Roger Olofsson Bagge, Marco Donia, Inge Marie Svane, Ola Nilsson, Lars Ny, Lisa M. Nilsson, Jonas A. Nilsson
Journal: Cancer Research
Cancer Res (2019) 79 (5): 899–904.
https://doi.org/10.1158/0008-5472.CAN-18-3158
Published: 01 March 2019
View articletitled, HER2 CAR-T Cells Eradicate Uveal Melanoma and T-cell Therapy–Resistant Human Melanoma in IL2 Transgenic NOD/SCID IL2 Receptor Knockout Mice
Open the PDF for HER2 CAR-T Cells Eradicate Uveal Melanoma and T-cell Therapy–Resistant Human Melanoma in IL2 Transgenic NOD/SCID IL2 Receptor Knockout Mice in another window
Includes: Supplementary data
Journal Articles

Acquired Immune Resistance Follows Complete Tumor Regression without Loss of Target Antigens or IFNγ Signaling

Marco Donia, Katja Harbst, Marit van Buuren, Pia Kvistborg, Mattias F. Lindberg, Rikke Andersen, Manja Idorn, Shamaila Munir Ahmad, Eva Ellebæk, Anja Mueller, Paolo Fagone, Ferdinando Nicoletti, Massimo Libra, Martin Lauss, Sine Reker Hadrup, Henrik Schmidt, Mads Hald Andersen, Per thor Straten, Jonas A. Nilsson, Ton N. Schumacher, Barbara Seliger, Göran Jönsson, Inge Marie Svane
Journal: Cancer Research
Cancer Res (2017) 77 (17): 4562–4566.
https://doi.org/10.1158/0008-5472.CAN-16-3172
Published: 31 August 2017
View articletitled, Acquired Immune Resistance Follows Complete Tumor Regression without Loss of Target Antigens or IFNγ Signaling
Open the PDF for Acquired Immune Resistance Follows Complete Tumor Regression without Loss of Target Antigens or IFNγ Signaling in another window
Includes: Supplementary data
Journal Articles

Abstract 5435: Beta-3 adrenergic antagonism can alleviate energy wasting associated with cancer-induced cachexia

Fredrick Anderson, Stefan K. Nilsson, Jonas A. Nilsson
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): 5435.
https://doi.org/10.1158/1538-7445.AM2017-5435
Published: 01 July 2017
View articletitled, Abstract 5435: Beta-3 adrenergic antagonism can alleviate energy wasting associated with cancer-induced cachexia
Journal Articles

Abstract 642: Hypoxia-regulated gene expression explains differences between cell line-derived xenografts and patient-derived xenografts

Joydeep Bhadury, Berglind O. Einarsdottir, Agnieszka Podraza, Roger Olofsson Bagge, Ulrika Stierner, Lars Ny, Marcela Dávila López, Jonas A. Nilsson
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): 642.
https://doi.org/10.1158/1538-7445.AM2016-642
Published: 15 July 2016
View articletitled, Abstract 642: Hypoxia-regulated gene expression explains differences between cell line-derived xenografts and patient-derived xenografts
Journal Articles

Abstract 967: Vemurafenib regulates miRNA-211 expression in melanoma - effects on extracellular vesicle RNA cargo and function

Taral R. Lunavat, Lesley Cheng, Berglind Einarsdottir, Cecilia Lässer, Jonas A. Nilsson, Andrew F. Hill, Jan Lötvall
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): 967.
https://doi.org/10.1158/1538-7445.AM2016-967
Published: 15 July 2016
View articletitled, Abstract 967: Vemurafenib regulates miRNA-211 expression in melanoma - effects on extracellular vesicle RNA cargo and function
Journal Articles

Cancer Differentiating Agent Hexamethylene Bisacetamide Inhibits BET Bromodomain Proteins

Lisa M. Nilsson, Lydia C. Green, Somsundar Veppil Muralidharan, Dağsu Demir, Martin Welin, Joydeep Bhadury, Derek T. Logan, Björn Walse, Jonas A. Nilsson
Journal: Cancer Research
Cancer Res (2016) 76 (8): 2376–2383.
https://doi.org/10.1158/0008-5472.CAN-15-2721
Published: 14 April 2016
View articletitled, Cancer Differentiating Agent Hexamethylene Bisacetamide Inhibits BET Bromodomain Proteins
Open the PDF for Cancer Differentiating Agent Hexamethylene Bisacetamide Inhibits BET Bromodomain Proteins in another window
Includes: Supplementary data
Journal Articles

Abstract LB-053: Monitoring rearrangement of EML4-ALK in blood platelets predicts outcome to crizotinib treatment in non-small-cell lung cancer patients

Jonas A. Nilsson, Niki Karachaliou, Pepijn Schellen, Ana Gimenez-Capitan, Jordi Berenguer, Cristina Teixido, Justine L. Kuiper, Esther Drees, Magda Grabowska, Marte van Keulen, Jihane M. Tannous, Danielle A.M. Heideman, Erik Thunnissen, Anne-Marie C. Dingemans, Santiago Viteri, Bakhos A. Tannous, Ana Drozdowskyj, Rafael Rosell, Egbert F. Smit, Thomas Wurdinger
Journal: Cancer Research
Cancer Res (2015) 75 (15_Supplement): LB-053.
https://doi.org/10.1158/1538-7445.AM2015-LB-053
Published: 01 August 2015
View articletitled, Abstract LB-053: Monitoring rearrangement of EML4-ALK in blood platelets predicts outcome to crizotinib treatment in non-small-cell lung cancer patients
Journal Articles

Abstract B38: Melanoma patient-derived xenografts accurately models the disease and develop fast enough to guide treatment decisions

Berglind O. Einarsdottir, Roger Olofsson Bagge, Joydeep Bhadury, Henrik Jespersen, Lisa M. Nilsson, Jan Mattsson, Katarina Truvé, Peter Naredi, Ola Nilsson, Marcela Davila Lopez, Ulrika Stierner, Lars Ny, Jonas A. Nilsson
Journal: Cancer Research
Cancer Res (2015) 75 (14_Supplement): B38.
https://doi.org/10.1158/1538-7445.MEL2014-B38
Published: 16 July 2015
View articletitled, Abstract B38: Melanoma patient-derived xenografts accurately models the disease and develop fast enough to guide treatment decisions
Journal Articles

Abstract A13: Decitabine treatment of c‐Myc transformed cancer cells is augmented by the removal of the checkpoint kinase Chk1

Andreas Höglund, Jonas A. Nilsson
Journal: Cancer Research
Cancer Res (2009) 69 (23_Supplement): A13.
https://doi.org/10.1158/0008-5472.FBCR09-A13
Published: 28 October 2014
View articletitled, Abstract A13: Decitabine treatment of c‐Myc transformed cancer cells is augmented by the removal of the checkpoint kinase Chk1
Journal Articles

Abstract 503: Antioxidants markedly accelerate tumor growth and reduce survival in mice with KRAS- and BRAF-induced lung cancer by disrupting the ROS-p53 axis

Volkan I. Sayin, Mohamed X. Ibrahim, Erik Larsson, Jonas A. Nilsson, Per Lindahl, Martin O. Bergö
Journal: Cancer Research
Cancer Res (2014) 74 (19_Supplement): 503.
https://doi.org/10.1158/1538-7445.AM2014-503
Published: 01 October 2014
View articletitled, Abstract 503: Antioxidants markedly accelerate tumor growth and reduce survival in mice with KRAS- and BRAF-induced lung cancer by disrupting the ROS-p53 axis
Journal Articles

Abstract 5495: BET bromodomain inhibitors abrogate cell cycle progression and induces apoptosis in Myc-induced mouse lymphoma cells without affecting MYC transcription

Joydeep Bhadury, Lisa M. Nilsson, Lydia Green, Zhoulei Li, Emily M. Gesner, Somsundar Veppil Muralidharan, Henrik C. Hansen, Ulrich B. Keller, Kevin G. Mclure, Jonas A. Nilsson
Journal: Cancer Research
Cancer Res (2014) 74 (19_Supplement): 5495.
https://doi.org/10.1158/1538-7445.AM2014-5495
Published: 01 October 2014
View articletitled, Abstract 5495: BET bromodomain inhibitors abrogate cell cycle progression and induces apoptosis in Myc-induced mouse lymphoma cells without affecting MYC transcription
Journal Articles

Abstract 4565: Bet bromodomain inhibitors affects replication & cell cycle progression

Somsundar Veppil Muralidharan, Joydeep Bhadury, Lydia Green, Lisa M. Nilsson, Kevin G. Mclure, Jonas A. Nilsson
Journal: Cancer Research
Cancer Res (2014) 74 (19_Supplement): 4565.
https://doi.org/10.1158/1538-7445.AM2014-4565
Published: 01 October 2014
View articletitled, Abstract 4565: Bet bromodomain inhibitors affects replication & cell cycle progression
Journal Articles

Id2 Is Dispensable for Myc-Induced Lymphomagenesis

Jonas A. Nilsson, Lisa M. Nilsson, Ulrich Keller, Yoshifumi Yokota, Kelli Boyd, John L. Cleveland
Journal: Cancer Research
Cancer Res (2004) 64 (20): 7296–7301.
https://doi.org/10.1158/0008-5472.CAN-04-2133
Published: 15 October 2004
View articletitled, Id2 Is Dispensable for Myc-Induced Lymphomagenesis
Open the PDF for Id2 Is Dispensable for Myc-Induced Lymphomagenesis in another window